Skip to main content
. 2017 Jan 26;17:87. doi: 10.1186/s12913-016-1931-3

Fig. 1.

Fig. 1

Outline of the Markov model assessing health outcomes of bedaquiline in high burden countries Source: adapted from [9] CE: cost-effectiveness; MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis. Note: MDR-TB population includes patients with MDR-TB as well as XDR-TB patients; transitions to the death state are possible from every state, but not shown on the diagram for clarity